Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Takeda Pharmaceutical Ltd ADR (NY: TAK )

16.43 +0.03 (+0.18%)
Official Closing Price Updated: 7:00 PM EDT, Mar 22, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,043,761
Open 16.36
Bid (Size) 16.18 (1)
Ask (Size) 17.00 (3)
Prev. Close 16.40
Today's Range 16.36 - 16.58
52wk Range 12.28 - 16.58
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Price Growth & Yield: For That Magical Combo, Leave the U.S.
Three foreign stocks, Takeda Pharmaceutical, United Microelectronics, and Coca-Cola FEMSA are showing that magical combination of growth and yield. 
Via MarketBeat
Takeda's Highest Dose Psoriasis Candidate Can Potentially Beat Bristol Myers' Approved Drug, Analyst Says
 
Via Benzinga

Performance

YTD
+4.25%
+4.25%
1 Month
+3.40%
+3.40%
3 Month
+6.69%
+6.69%
6 Month
+26.48%
+26.48%
1 Year
+9.75%
+9.75%

More News

Read More
Takeda Announces Positive Results in Phase 2b Study of Investigational TAK-279, an Oral, Once-Daily TYK2 Inhibitor, in People with Moderate-to-Severe Plaque Psoriasis
From Takeda Pharmaceutical Company Limited
Via Business Wire
Takeda Pharmaceutical Co. Ltd. (NYSE: TAK) Sets New 52-Week High in Friday Session
Via Investor Brand Network
Zoetis Stock Shows Rising Relative Strength Upgrades
Via Investor's Business Daily
Current Report: Takeda Pharmaceutical (TAK)
Via Talk Markets
HUTCHMED Out Licenses Fruquintinib To Takeda Outside China
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 16, 2023
Via Benzinga
Johnson & Johnson's Experimental Dengue Pill Shows Efficacy In Animal Studies
Via Benzinga
HUTCHMED Announces Closing of Fruquintinib License to Takeda Outside China
From HUTCHMED (China) Limited
Via Globe NewsWire
Should You Give Up on Novavax?
Via The Motley Fool
Intellia Therapeutics Stock Surges On A First-Ever In CRISPR Gene Editing
Via Investor's Business Daily
2 Incredibly Cheap High-Yield Dividend Stocks to Buy Now
Via The Motley Fool
Takeda Presents Vedolizumab Data For Preventing Graft-Versus-Host Disease In Stem Cell Transplant Patients
Via Benzinga
Takeda Presents Positive Results from Phase 3 Study of Vedolizumab for Prevention of Intestinal Acute Graft-Versus-Host Disease (aGvHD) in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
From Takeda Pharmaceutical Company Limited
Via Business Wire
Is This the Telltale Sign to Sell Novavax Stock?
Via The Motley Fool
Takeda Completes Acquisition of Nimbus Therapeutics’ TYK2 Program Subsidiary
From Takeda Pharmaceutical Company Limited
Via Business Wire
NeurAxis: Should You Buy This IPO?
Via Talk Markets
NeurAxis IPO Sets Stage To Take On Irritable Bowel Syndrome With A Non-Surgical Solution
Via Talk Markets
U.S. FDA Approves Takeda’s TAKHZYRO® (lanadelumab-flyo) to Prevent Hereditary Angioedema (HAE) Attacks in Children 2 Years of Age and Older
From Takeda Pharmaceutical Company Limited
Via Business Wire
Takeda Reports 13% Fall In Nine Month Operating Profit, Keeps Annual Guidance Unchanged
Via Benzinga
Takeda Reinforces Long-term Growth Through Pipeline Advancement and Two Targeted Acquisitions; Delivers Another Strong Quarter in FY2022 Q3
From Takeda Pharmaceutical Company Limited
Via Business Wire
7 Sorry Dividend Stocks to Sell in February Before It’s Too Late
Via InvestorPlace
Week In Review: HutchMed Announces $1.1 Billion Deal With Takeda For Colorectal Cancer Drug
Via Talk Markets
Finch Therapeutics Halts Work On Its Only Clinical Stage Asset, Cuts 95% Of Workforce
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.